Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.36 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.36 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.35 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18606218 | 0.88 | KDM4E (0.35) | POLBSLC16A3SLC16A1 | |
| SCHEMBL3208116 | 0.85 | POLB (0.41) | TSHRSMN1; SMN2POLBSLC16A3SLC16A1 | |
| SCHEMBL1274455 | 0.84 | KDM4E (0.39) | SLC16A3SLC16A1 | |
| SCHEMBL530510 | 0.81 | ACE2 (0.41) | POLBGPR84FFAR1MAPTLCK | |
| SCHEMBL22092354 | 0.78 | EP300 (0.46) | TSHRSMN1; SMN2GPR84FFAR1MAPT | |
| SCHEMBL1275723 | 0.77 | POLB (0.39) | TSHRPOLBSLC16A3SLC16A1 | |
| SCHEMBL604709 | 0.76 | LCK (0.44) | TSHRSMN1; SMN2GPR84FFAR1MAPT | |
| SCHEMBL18556754 | 0.75 | ZDHHC7 (0.41) | SMN1; SMN2POLBGPR84FFAR1MAPT | |
| SCHEMBL25358949 | 0.75 | LCK (0.47) | TSHRSMN1; SMN2GPR84FFAR1MAPT | |
| SCHEMBL5826081 | 0.75 | LCK (0.47) | TSHRSMN1; SMN2GPR84FFAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230138395-A1 | PHARMACEUTICAL COMPOSITIONS OF A THERAPEUTIC POLYENE MACROLIDE AND METHODS OF THEIR USE | BIOSERGEN AS (NO) | 2023-05-04 | — | — | US | disclosed |
| EP-4110305-A1 | PHARMACEUTICAL COMPOSITIONS OF A THERAPEUTIC POLYENE MACROLIDE AND METHODS OF THEIR USE | Biosergen AS (NO) | 2023-01-04 | — | — | EP | disclosed |
| EP-1647262-B2 | Anhydrous cosmetic composition comprising electrophilic monomers and acid, and use for cosmetic treatment of hair | OREAL (FR) | 2012-02-08 | — | — | EP | disclosed |
| EP-1647262-B1 | Anhydrous cosmetic composition comprising electrophilic monomers and acid, and use for cosmetic treatment of hair | OREAL (FR) | 2009-08-05 | — | — | EP | disclosed |
| EP-2065026-A1 | Composition comprising, in an anhydrous cosmetically acceptable medium, electrophilic monomers and an acid, and its use for cosmetic treatment of hair | L'Oreal (FR) | 2009-06-03 | — | — | EP | disclosed |
| EP-1649898-A2 | Dye composition comprising a pigment and at least one specific electrophilic monomer | L'OREAL (FR) | 2006-04-26 | — | — | EP | disclosed |
| EP-1649894-A2 | Composition comprising electrophilic monomers and organic salts, use for treatment of keratinic materials | L'OREAL (FR) | 2006-04-26 | — | — | EP | disclosed |
| EP-1649896-A2 | Dye composition comprising a mixtrure of pigment and electophilic monomer | L'OREAL (FR) | 2006-04-26 | — | — | EP | disclosed |
| EP-1649895-A2 | Oxidizing composition comprising at least one electrophilic monomer and an oxidant with exception of benzoquinone | L'OREAL (FR) | 2006-04-26 | — | — | EP | disclosed |
| EP-1649897-A2 | Dye composition comprising a pigment and at least an electrophilic monomer | L'OREAL (FR) | 2006-04-26 | — | — | EP | disclosed |
| EP-1647260-A1 | use for cosmetic treatment of keratinic material of a composition comprising an electrophilic monomer and a non-siloxane polymer, thereby achieving a soft coating | L'OREAL (FR) | 2006-04-19 | — | — | EP | disclosed |
| EP-1647264-A1 | use for cosmetic treatment of keratinic material of a composition comprising an electrophilic monomer and a non-siloxane polymer, thereby achieving a rigid coating | L'OREAL (FR) | 2006-04-19 | — | — | EP | disclosed |
| EP-1647259-A1 | use for treatment of keratinic materials of compositions comprising electrophilic monomers and agents forming liquid crystals | L'OREAL (FR) | 2006-04-19 | — | — | EP | disclosed |
| EP-1647265-A1 | Use for the cosmetic treatment of keratinous material of non sticky compositions based on electrophilic monomeres and non-silicon polymers | L'OREAL (FR) | 2006-04-19 | — | — | EP | disclosed |
| EP-1647258-A1 | Hair care composition based on electrophilic monomers and lubricating solid micro or nano particles | L'OREAL (FR) | 2006-04-19 | — | — | EP | disclosed |
| EP-1647263-A1 | Double chamber aerosol device comprising electrophilic monomers and use for the cosmetic treatment of hair | L'OREAL (FR) | 2006-04-19 | — | — | EP | disclosed |
| EP-1647261-A1 | Composition for the treatment of keratinous material based on electrophilic monomers and salts | L'OREAL (FR) | 2006-04-19 | — | — | EP | disclosed |
| EP-1647262-A1 | Anhyrous cosmetic composition comprising electrophilic monomers and acid, and use for cosmetic treatment of hair | L'OREAL (FR) | 2006-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230138395-A1 | PHARMACEUTICAL COMPOSITIONS OF A THERAPEUTIC POLYENE MACROLIDE AND METHODS OF THEIR USE | CEL, LIPA, HDAC6 | TSHR 4097/4885SMN1; SMN2 744/4885POLB 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.